The estimated Net Worth of Global Investors Lp Viking ... is at least $383 Million dollars as of 5 March 2024. Global Viking owns over 3,038,617 units of Inhibrx stock worth over $585,480 and over the last few years Global sold INBX stock worth over $381,983,116.
Sign up
Global Viking INBX stock SEC Form 4 insiders trading
Global has made over 3 trades of the Inhibrx stock since 2024, according to the Form 4 filled with the SEC. Most recently Global sold 1,951,782 units of INBX stock worth $74,460,483 on 17 June 2024.
The largest trade Global's ever made was selling 6,500,000 units of Inhibrx stock on 2 January 2024 worth over $203,450,000. On average, Global trades about 2,298,080 units every 33 days since 2024. As of 5 March 2024 Global still owns at least 39,032 units of Inhibrx stock.
You can see the complete history of Global Viking stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Inhibrx
Over the last 4 years, insiders at Inhibrx have traded over $27,711,393 worth of Inhibrx stock and bought 2,717,119 units worth $64,845,764 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management, L.P.Kol... und Global Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of $1,598,400. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth $671,000.
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
What does Inhibrx's logo look like?
Complete history of Global Viking stock trades at APi und Inhibrx
Inhibrx executives and stock owners
Inhibrx executives and other stock owners filed with the SEC include:
-
Mark Paul Lappe,
Founder, Chairman, Pres & CEO -
Dr. Klaus W. Wagner,
Chief Medical Officer & Exec. VP -
Dr. Brendan P. Eckelman Ph.D.,
Founder, Chief Scientific Officer & Exec. VP of Corp. Strategy -
Kelly Devine Deck B.S., CPA, M.S.,
Chief Financial Officer -
Klaus Wagner,
Executive Vice President, Chief Medical Officer -
Kelly Deck,
Chief Financial Officer -
Quinn Deveraux,
Co-Founder, Executive Vice President - Early Research -
Brendan Eckelman,
Co-Founder, Executive Vice President - Corporate Strategy, Chief Scientific Officer -
Mark Lappe,
Chairman of the Board, Chief Executive Officer, Founder -
David Matly M.B.A.,
Exec. VP & Chief Commercial Officer -
Jeffrey J. Jensen,
Exec. VP of Clinical Operations -
Leah Pollema J.D.,
VP, Corp. Sec. & Gen. Counsel -
Dr. Ashraf Amanullah,
Exec. VP & Chief Technical Operations Officer -
Capital Management, L.P.Kol...,
-
Brendan P. Eckelman,
Chief Scientific Officer -
Jon Faiz Kayyem,
Director -
Global Investors Lp Viking ...,
-
Kristiina Md Vuori,
Director -
Douglas Forsyth,
Director -
Kimberly Manhard,
Director -
Global Investors Lp Viking ...,
-
Inc. Inhibrx,,
-
Mark Lappe,
Chief Executive Officer